U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266376) titled 'Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS' on Nov. 14.
Brief Summary: Approximately 25-50% of patients with schizophrenia experience treatment-resistant Auditory Verbal Hallucinations (AVHs), which contribute to the development of associated psychopathological disorders (e.g., anxiety, depression, suicidal ideation). Various validated psychotherapeutic strategies and tools for managing treatment-resistant AVHs have been combined into an integrative therapeutic program. The main objective of this study is to evaluate the efficacy of this program in reducing the frequency and intensity of AVHs, as well as it...